Dr. John Hurrell joined Ferghana in 2013 as Strategic Transaction Advisor, Diagnostics/Tools Sector, to augment the firm’s scientific expertise.
John was Senior Executive Vice President International of Seegene [Seoul, Korea], where he was responsible for global sales, licensing, OEM, and companion diagnostic deals. Most recently he was SVP, International Business, President, APAC for PTS Diagnostics (recently acquired by Sinocare Inc. (China)), Founder/Chairman of PTS Diagnostics India and Chairman, Anteo Diagnostics (Australia). He currently serves as Advisor to several global diagnostics companies.
John has a distinguished track record of growing companies in the healthcare industry, including the Focus Diagnostics product subsidiary of Quest Diagnostics (acquired by Diasorin). At Focus, he was the president and general manager where he led the development and launch of more than 70 molecular diagnostic tests and successfully gained 510(k) approvals for six products. Previously, John served as VP of Business Development at Quest Diagnostics.
In his earlier days John was SVP R&D Operations for Boehringer Mannheim (now Roche Diagnostics) where he was responsible for the development of the blood glucose monitoring system AccuChek Advantage and other highly successful POC products.
John is a Harvard Medical School Fulbright Fellow (monoclonal antibody technologies) and has a PhD in Biochemistry/Immunology and a Bachelor of Science in Biochemistry/Chemistry from Melbourne University.